Zobrazeno 1 - 10
of 53
pro vyhledávání: '"Michael, Hedenus"'
Autor:
Ulrich Jaeger, Marek Trneny, Helen Melzer, Michael Praxmarer, Weerasak Nawarawong, Dina Ben Yehuda, David Goldstein, Bilijana Mihaljevic, Osman Ilhan, Veronika Ballova, Michael Hedenus, Liang-Tsai Hsiao, Wing-Yan Au, Sonja Burgstaller, Gerhard Weidinger, Felix Keil, Christian Dittrich, Cathrin Skrabs, Anton Klingler, Andreas Chott, Michael A. Fridrik, Richard Greil
Publikováno v:
Haematologica, Vol 100, Iss 7 (2015)
We investigated rituximab maintenance therapy in patients with diffuse large B-cell lymphoma (n=662) or follicular lymphoma grade 3b (n=21) in first complete remission. Patients were randomized to rituximab maintenance (n=338) or observation (n=345).
Externí odkaz:
https://doaj.org/article/e4ed4d06af08447a81949f26f4ec0900
Autor:
David Rampton, Joergen Folkersen, Steven Fishbane, Michael Hedenus, Stefanie Howaldt, Francesco Locatelli, Shalini Patni, Janos Szebeni, Guenter Weiss
Publikováno v:
Haematologica, Vol 99, Iss 11 (2014)
Intravenous iron is widely used for the treatment of iron deficiency anemia when oral iron is inappropriate, ineffective or poorly tolerated. Acute hypersensitivity reactions during iron infusions are very rare but can be life-threatening. This paper
Externí odkaz:
https://doaj.org/article/8db2d2a6b716448f9b955184a5c64b6c
Autor:
Bernard Favrat, Katharina Balck, Christian Breymann, Michael Hedenus, Thomas Keller, Anna Mezzacasa, Christoph Gasche
Publikováno v:
PLoS ONE, Vol 9, Iss 4, p e94217 (2014)
Unexplained fatigue is often left untreated or treated with antidepressants. This randomized, placebo-controlled, single-blinded study evaluated the efficacy and tolerability of single-dose intravenous ferric carboxymaltose (FCM) in iron-deficient, p
Externí odkaz:
https://doaj.org/article/a5324c382b9446408a184238c195d64b
Autor:
Steven Fishbane, Francesco Locatelli, S. Howaldt, S. Patni, Günter Weiss, Janos Szebeni, David S. Rampton, Michael Hedenus, J. Folkersen
Publikováno v:
British Journal of Pharmacology. 172:5025-5036
Intravenous (IV) iron therapy is widely used in iron deficiency anaemias when oral iron is not tolerated or ineffective. Administration of IV-iron is considered a safe procedure, but severe hypersensitivity reactions (HSRs) can occur at a very low fr
Autor:
Shalini Patni, Joergen Folkersen, Michael Hedenus, Janos Szebeni, David S. Rampton, Francesco Locatelli, Stefanie Howaldt, Guenter Weiss, Steven Fishbane
Publikováno v:
Haematologica. 99:1671-1676
Intravenous iron is widely used for the treatment of iron deficiency anemia when oral iron is inappropriate, ineffective or poorly tolerated. Acute hypersensitivity reactions during iron infusions are very rare but can be life-threatening. This paper
Publikováno v:
Cancer Medicine
Pharmacovigilance (PV) is the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or other problems related to medical products after they have been licensed for marketing. The purpose of PV
Publikováno v:
Current Medical Research and Opinion. 29:325-337
Prior to the approval of the first erythropoiesis-stimulating agent (ESA) in the early 1990s, red blood cell transfusions were the primary means of treating severe chemotherapy-induced anemia (CIA), with little recourse for those with more mild forms
Autor:
Johan Vansteenkiste, Laura Belton, Michael Hedenus, Jan-Henrik Terwey, Enrique Hernandez, Robert Pirker
Purpose Limited data are available to describe the effectiveness of darbepoetin alfa (DA) in terms of hemoglobin (Hb) and transfusion outcomes when initiated at Hb ≤10 g/dL (the threshold specified in the summary of prescribing characteristics). We
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aaf5c25012222800bdd02cfdef8a0e6c
https://lirias.kuleuven.be/handle/123456789/531793
https://lirias.kuleuven.be/handle/123456789/531793
Publikováno v:
Leukemia & Lymphoma
Erythropoiesis-stimulating agents (ESAs) are approved to treat anemia in patients with non-myeloid malignancies receiving myelosuppressive chemotherapy. ESAs reduce transfusion rates, but some clinical studies suggest that ESAs may reduce survival or
Autor:
Johan Vansteenkiste, Jean-Luc Canon, Ken Bridges, B. Pujol, Carsten Bokemeyer, Heinz Ludwig, Jason C. Legg, Pere Gascón, Jan B. Vermorken, Michael Hedenus
Publikováno v:
Medical Oncology. 29:2291-2299
Darbepoetin alfa (DA) is an erythropoiesis-stimulating agent (ESA) approved for treating chemotherapy-induced anemia (CIA). Safety concerns have prompted changes to the ESA-product information, which now recommends initiating ESAs at hemoglobin (Hb)